These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 19407299

  • 1. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement.
    Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR.
    J Bone Joint Surg Br; 2009 May; 91(5):636-44. PubMed ID: 19407299
    [Abstract] [Full Text] [Related]

  • 2. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies.
    Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK.
    Thromb Haemost; 2011 Mar; 105(3):444-53. PubMed ID: 21136019
    [Abstract] [Full Text] [Related]

  • 3. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
    Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W, RECORD1 Study Group.
    N Engl J Med; 2008 Jun 26; 358(26):2765-75. PubMed ID: 18579811
    [Abstract] [Full Text] [Related]

  • 4. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators.
    Circulation; 2006 Nov 28; 114(22):2374-81. PubMed ID: 17116766
    [Abstract] [Full Text] [Related]

  • 5. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
    Huisman MV, Quinlan DJ, Dahl OE, Schulman S.
    Circ Cardiovasc Qual Outcomes; 2010 Nov 28; 3(6):652-60. PubMed ID: 20923996
    [Abstract] [Full Text] [Related]

  • 6. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
    Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG, RECORD3 Investigators.
    N Engl J Med; 2008 Jun 26; 358(26):2776-86. PubMed ID: 18579812
    [Abstract] [Full Text] [Related]

  • 7. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E.
    Health Technol Assess; 2009 Oct 26; 13 Suppl 3():43-8. PubMed ID: 19846028
    [Abstract] [Full Text] [Related]

  • 8. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
    Raskob GE, Gallus AS, Pineo GF, Chen D, Ramirez LM, Wright RT, Lassen MR.
    J Bone Joint Surg Br; 2012 Feb 26; 94(2):257-64. PubMed ID: 22323697
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of rivaroxaban after total hip or total knee arthroplasty.
    Kwong LM.
    Am J Manag Care; 2011 Feb 26; 17(1 Suppl):S22-6. PubMed ID: 21517652
    [Abstract] [Full Text] [Related]

  • 10. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
    Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S, RECORD2 Investigators.
    Lancet; 2008 Jul 05; 372(9632):31-9. PubMed ID: 18582928
    [Abstract] [Full Text] [Related]

  • 11. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
    Friedman RJ, Dahl OE, Rosencher N, Caprini JA, Kurth AA, Francis CW, Clemens A, Hantel S, Schnee JM, Eriksson BI, RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees.
    Thromb Res; 2010 Sep 05; 126(3):175-82. PubMed ID: 20434759
    [Abstract] [Full Text] [Related]

  • 12. Dose-escalation study of rivaroxaban (BAY 59-7939)--an oral, direct Factor Xa inhibitor--for the prevention of venous thromboembolism in patients undergoing total hip replacement.
    Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Muehlhofer E, Kälebo P.
    Thromb Res; 2007 Sep 05; 120(5):685-93. PubMed ID: 17292948
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
    Weitz JI, Cao C, Eriksson BI, Fisher W, Kupfer S, Raskob G, Spaeder J, Turpie AG.
    Thromb Haemost; 2010 Dec 05; 104(6):1150-7. PubMed ID: 20886185
    [Abstract] [Full Text] [Related]

  • 16. Oral rivaroxaban for symptomatic venous thromboembolism.
    EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S.
    N Engl J Med; 2010 Dec 23; 363(26):2499-510. PubMed ID: 21128814
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Apixaban and rivaroxaban decrease deep venous thrombosis but not other complications after total hip and total knee arthroplasty.
    Russell RD, Huo MH.
    J Arthroplasty; 2013 Oct 23; 28(9):1477-81. PubMed ID: 23540535
    [Abstract] [Full Text] [Related]

  • 20. A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment.
    Turpie AG, Haas S, Kreutz R, Mantovani LG, Pattanayak CW, Holberg G, Jamal W, Schmidt A, van Eickels M, Lassen MR.
    Thromb Haemost; 2014 Jan 23; 111(1):94-102. PubMed ID: 24154549
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.